Fluoropharm

FluoroPharm is a biotechnology company specializing in the discovery and development of fluorine-18 labeled radiopharmaceuticals for molecular imaging. Founded by Dr. Hank Kung, a pioneer in PET tracer chemistry, the company focuses on creating diagnostic agents for neurodegenerative diseases and oncology. Its technology platform enables the visualization of critical biomarkers such as amyloid plaques and vesicular monoamine transporters in the living brain. The company's research has led to significant breakthroughs in Alzheimer's disease diagnostics, including the early development of assets later licensed to major pharmaceutical players. FluoroPharm continues to advance a pipeline of novel tracers targeting the Sigma-1 receptor and other metabolic pathways.